Free Trial
$100 Off. Every Year. Lock In MarketBeat All Access at $149
Claim the Rate Lock
Claim MarketBeat All Access Sale Promotion
NYSE:RCUS

Arcus Biosciences Q3 2026 Earnings Date & Estimates

Arcus Biosciences logo
$18.54 -0.82 (-4.22%)
Closing price 10/23/2026 03:59 PM Eastern
Extended Trading
$18.57 +0.03 (+0.17%)
As of 10/23/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arcus Biosciences is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. The conference call is scheduled for November 3, 2026 at 4:00 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call Date
Conference Call
4:00 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Arcus Biosciences in Q3 2026

Arcus Biosciences is expected to post earnings of -$0.8912 per share on revenue of $7.58 million. In the same quarter a year earlier Arcus Biosciences reported -$1.27 per share. Arcus Biosciences last reported on August 5, 2026, posting -$0.72 per share and beating the -$0.8912 consensus estimate. Arcus Biosciences has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.8912
Expected Revenue
$7.58 million
Prior-Year EPS
-$1.27

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.72 (Beat by +$0.1712)
Last Quarter Revenue
$41.00 million
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

Arcus Biosciences Q3 2026 Earnings FAQ

Arcus Biosciences (NYSE:RCUS) is estimated to report Q3 2026 earnings on Wednesday, November 4, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Arcus Biosciences' Q3 2026 earnings conference call is scheduled for Tuesday, November 3, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Arcus Biosciences to post earnings of -$0.8912 per share for Q3 2026.

The consensus revenue estimate for Arcus Biosciences is $7.58 million for Q3 2026.

Arcus Biosciences' next earnings date is estimated for Tuesday, October 27, 2026. MarketBeat tracks confirmed and estimated earnings dates for Arcus Biosciences on the company's earnings history page.

Arcus Biosciences Earnings Headlines

Arcus Biosciences (RCUS) Stock Looks Stretched As Casdatifan Trial Data Impresses
October 24 at 7:05 PM  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/arcus-biosciences-rcus-stock-looks-190912493.html
Arcus Biosciences (NYSE:RCUS) Sees Strong Trading Volume on Analyst Upgrade
October 24 at 1:52 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31151664
He turned $12K into $1.65M without touching Apple or Tesla
Tim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading Apple, Tesla, or Bitcoin. He targets overlooked small-cap stocks that can move fast: $1.50 to $98.40 in a week, $6 to $34 in hours, or 49 cents to $10 in days. Now he is sharing the exact setup he watches for before these moves happen.tc pixel
October 25 at 1:00 AM  |  Tim Sykes (Ad)
Arcus Biosciences (NYSE:RCUS) Stock Moved Down to "Sell" by Wall Street Zen
October 24 at 1:19 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31151470
Arcus Biosciences, Inc. closes public offering of 16,428,572 shares of common stock for net proceeds of approximately $269.7 million
October 23 at 11:01 PM  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/arcus-biosciences-inc-closes-public-offering-of-16-428-572-shares-of-common-stock-for-net-proceeds-of-approximately-269-7-million/ar-AA2fWIj9
Arcus Biosciences Completes $269 Million Common Stock Offering
October 23 at 4:30 PM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/arcus-biosciences-completes-269-million-common-stock-offering?utm_source=marketbeat.com&utm_medium=referral
See More Arcus Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Arcus Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arcus Biosciences and other key companies, straight to your email.

About Arcus Biosciences

Arcus Biosciences (NYSE:RCUS) is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company uses its research platform to discover and advance medicines designed to target immune suppression and other biological mechanisms involved in tumor growth.

Arcus’s oncology pipeline has included antibody-based and small-molecule therapies aimed at targets such as TIGIT, PD-1, CD73, and the adenosine A2A and A2B receptors. Its key development programs have included domvanalimab, zimberelimab, quemliclustat, and etrumadenant, which have been evaluated in clinical studies across several cancer types, including lung, gastrointestinal, and colorectal cancers.

Founded in 2015 and headquartered in Hayward, California, Arcus conducts research and clinical-development activities intended to support potential commercialization in international markets. The company has maintained a strategic collaboration with Gilead Sciences, which has supported the development and potential commercialization of several Arcus programs. Arcus was co-founded by Terry Rosen and Juan Jaén; Rosen has served as chief executive officer, while Jaén has held senior leadership roles focused on research and development.

View Arcus Biosciences Profile
Earnings Tools